Wilmington Savings Fund Society FSB Acquires Shares of 1,202 argenx SE (NASDAQ:ARGX)

Wilmington Savings Fund Society FSB acquired a new position in argenx SE (NASDAQ:ARGX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,202 shares of the company's stock, valued at approximately $652,000.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC increased its stake in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Perpetual Ltd purchased a new stake in argenx in the third quarter worth $76,314,000. Logos Global Management LP purchased a new stake in argenx in the second quarter worth $58,055,000. Wellington Management Group LLP raised its stake in shares of argenx by 13.0% in the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company's stock valued at $261,470,000 after buying an additional 55,617 shares during the period. Finally, Sei Investments Co. lifted its position in shares of argenx by 15.2% during the 2nd quarter. Sei Investments Co. now owns 381,544 shares of the company's stock valued at $164,079,000 after buying an additional 50,477 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

argenx Trading Up 4.2 %

Shares of ARGX traded up $25.43 during midday trading on Monday, reaching $632.64. The stock had a trading volume of 222,159 shares, compared to its average volume of 307,781. The company has a market capitalization of $38.19 billion, a price-to-earnings ratio of -718.91 and a beta of 0.59. The company's 50-day moving average is $583.23 and its 200 day moving average is $517.38. argenx SE has a 12-month low of $327.73 and a 12-month high of $643.63.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter in the prior year, the firm earned ($1.25) earnings per share. Research analysts forecast that argenx SE will post 2.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Scotiabank raised shares of argenx from a "sector perform" rating to a "sector outperform" rating and raised their price objective for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. Baird R W lowered argenx from a "strong-buy" rating to a "hold" rating in a report on Friday, November 1st. JPMorgan Chase & Co. boosted their price objective on argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research note on Monday, November 4th. Truist Financial raised their target price on argenx from $540.00 to $660.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut argenx from a "buy" rating to a "hold" rating in a research report on Friday, October 4th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, argenx has a consensus rating of "Moderate Buy" and an average target price of $635.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.